108 related articles for article (PubMed ID: 22406415)
1. Neuroprotective effects of extremely low-frequency electromagnetic fields on a Huntington's disease rat model: effects on neurotrophic factors and neuronal density.
Tasset I; Medina FJ; Jimena I; Agüera E; Gascón F; Feijóo M; Sánchez-López F; Luque E; Peña J; Drucker-Colín R; Túnez I
Neuroscience; 2012 May; 209():54-63. PubMed ID: 22406415
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes.
Rossignol J; Boyer C; Lévèque X; Fink KD; Thinard R; Blanchard F; Dunbar GL; Lescaudron L
Behav Brain Res; 2011 Mar; 217(2):369-78. PubMed ID: 21070819
[TBL] [Abstract][Full Text] [Related]
3. Fifty hertz extremely low-frequency magnetic field exposure elicits redox and trophic response in rat-cortical neurons.
Di Loreto S; Falone S; Caracciolo V; Sebastiani P; D'Alessandro A; Mirabilio A; Zimmitti V; Amicarelli F
J Cell Physiol; 2009 May; 219(2):334-43. PubMed ID: 19115234
[TBL] [Abstract][Full Text] [Related]
4. IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats.
Escartin C; Boyer F; Bemelmans AP; Hantraye P; Brouillet E
Neurosci Lett; 2007 Oct; 425(3):167-72. PubMed ID: 17868993
[TBL] [Abstract][Full Text] [Related]
5. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
Ramaswamy S; McBride JL; Herzog CD; Brandon E; Gasmi M; Bartus RT; Kordower JH
Neurobiol Dis; 2007 May; 26(2):375-84. PubMed ID: 17336076
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
Emerich DF; Winn SR; Hantraye PM; Peschanski M; Chen EY; Chu Y; McDermott P; Baetge EE; Kordower JH
Nature; 1997 Mar; 386(6623):395-9. PubMed ID: 9121555
[TBL] [Abstract][Full Text] [Related]
7. 17 beta-Estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats.
Túnez I; Collado JA; Medina FJ; Peña J; Del C Muñoz M; Jimena I; Franco F; Rueda I; Feijóo M; Muntané J; Montilla P
Neurochem Int; 2006 Apr; 48(5):367-73. PubMed ID: 16420966
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Kumar P; Kumar A
Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease.
de Almeida LP; Zala D; Aebischer P; Déglon N
Neurobiol Dis; 2001 Jun; 8(3):433-46. PubMed ID: 11442352
[TBL] [Abstract][Full Text] [Related]
10. Melatonin improves 3-nitropropionic acid induced behavioral alterations and neurotrophic factors levels.
Tasset I; Agüera E; Olmo-Camacho R; Escribano B; Sánchez-López F; Delgado MJ; Cruz AH; Gascón F; Luque E; Peña J; Jimena IM; Túnez I
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1944-9. PubMed ID: 21939726
[TBL] [Abstract][Full Text] [Related]
11. Magnetic field exposure saves rat cerebellar granule neurons from apoptosis in vitro.
Oda T; Koike T
Neurosci Lett; 2004 Jul; 365(2):83-6. PubMed ID: 15245783
[TBL] [Abstract][Full Text] [Related]
12. Acute neuroprotective effects of extremely low-frequency electromagnetic fields after traumatic brain injury in rats.
Yang Y; Li L; Wang YG; Fei Z; Zhong J; Wei LZ; Long QF; Liu WP
Neurosci Lett; 2012 May; 516(1):15-20. PubMed ID: 22484017
[TBL] [Abstract][Full Text] [Related]
13. Chronic exposure to 50Hz magnetic fields causes a significant weakening of antioxidant defence systems in aged rat brain.
Falone S; Mirabilio A; Carbone MC; Zimmitti V; Di Loreto S; Mariggiò MA; Mancinelli R; Di Ilio C; Amicarelli F
Int J Biochem Cell Biol; 2008; 40(12):2762-70. PubMed ID: 18585472
[TBL] [Abstract][Full Text] [Related]
14. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
[TBL] [Abstract][Full Text] [Related]
15. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease.
Lee ST; Park JE; Kim DH; Kim S; Im WS; Kang L; Jung SH; Kim MW; Chu K; Kim M
Brain Res; 2008 Feb; 1194():130-7. PubMed ID: 18166168
[TBL] [Abstract][Full Text] [Related]
17. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
[TBL] [Abstract][Full Text] [Related]
18. Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-nitropropionic model of Huntington's disease.
Túnez I; Drucker-Colín R; Jimena I; Medina FJ; Muñoz Mdel C; Peña J; Montilla P
J Neurochem; 2006 May; 97(3):619-30. PubMed ID: 16524377
[TBL] [Abstract][Full Text] [Related]
19. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III).
Pérez-De La Cruz V; González-Cortés C; Galván-Arzate S; Medina-Campos ON; Pérez-Severiano F; Ali SF; Pedraza-Chaverrí J; Santamaría A
Neuroscience; 2005; 135(2):463-74. PubMed ID: 16111817
[TBL] [Abstract][Full Text] [Related]
20. Neurotrophic enhancers as therapy for behavioral deficits in rodent models of Huntington's disease: use of gangliosides, substituted pyrimidines, and mesenchymal stem cells.
Dunbar GL; Sandstrom MI; Rossignol J; Lescaudron L
Behav Cogn Neurosci Rev; 2006 Jun; 5(2):63-79. PubMed ID: 16801683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
